Form 4: PTC Therapeutics CBO Sells Shares for Tax Obligations

PTC Therapeutics' Chief Business Officer, Eric Pauwels, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Eric Pauwels, Chief Business Officer of PTC Therapeutics, Inc. (PTCT), reported two transactions involving the sale of common stock.
• On January 6, 2026, Pauwels sold 1,789 shares of common stock at a price of $76.95 per share.
• This sale was executed to satisfy tax withholding obligations in connection with the vesting of 5,500 Restricted Stock Units (RSUs) from a January 3, 2025 grant of 22,000 RSUs.
• On January 7, 2026, an additional 1,352 shares of common stock were sold at a price of $77.48 per share.
• This second sale also covered tax withholding obligations related to the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.
• Both transactions were automatic sales pursuant to an irrevocable 'sell to cover' election, entered into upon acceptance of the grant, and were made under a Rule 10b5-1(c) plan.
• Following these transactions, Pauwels beneficially owns 87,489 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary insider transaction for tax purposes related to RSU vesting, which is a common occurrence and does not reflect a discretionary positive or negative view on the company's prospects by the insider.

Positives

• The underlying event for the sales was the vesting of Restricted Stock Units (RSUs), indicating the executive's compensation and retention incentives are being realized.
• The transactions were pre-planned under a Rule 10b5-1(c) contract, instruction, or written plan, suggesting a structured and non-discretionary approach to managing equity compensation and tax liabilities.

Negatives

• The transactions represent a reduction in the Chief Business Officer's direct beneficial ownership of common stock by a total of 3,141 shares.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and tax obligations, which is common across all industries, particularly in publicly traded companies that use Restricted Stock Units (RSUs) as part of executive compensation packages. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-planned sales for tax purposes and do not signal a change in management's confidence or a significant shift in ownership structure.
• Employees: No direct impact mentioned, but the vesting of RSUs is part of executive compensation, which can be a general positive for employee morale regarding equity programs.

Key Dates

Recommendation

The filing details routine 'sell to cover' transactions by an executive to satisfy tax obligations upon RSU vesting. These pre-planned sales under Rule 10b5-1 are not indicative of a change in the company's fundamentals or the executive's long-term view. Therefore, this specific filing does not provide new information that would warrant a change from a 'hold' recommendation.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Eric Pauwels, Chief Business Officer, Rule 10b5-1